If you have been diagnosed with idiopathic short stature, you will probably find that your health insurance does not cover the cost of treating you. However, there are several steps you can take to obtain coverage for your treatment, including getting your doctor’s office to file an appeal on your behalf.

Request that your doctor’s office send an appeal

The premise behind the request that your doctor’s office sends an appeal to get health insurance to cover human growth hormone is simple: your doctor has prescribed a drug that is expensive and you need it. Despite your best efforts, however, your insurance company may deny the claim.

First, you must make sure that you understand what your state’s insurance laws are. Your doctor’s office can help you with this, but it’s a good idea to do your homework as well. Whether your health insurance plan is managed by your employer or your own insurer, it’s a good idea to know what your options are. In fact, your insurer may even have a set of guidelines that you must follow.

Second, you can try to write an appeal yourself. If you’re not in the medical field, you’ll want to find a GH company coordinator to do it for you. You can also check out the External Appeals Database. This website allows you to search by diagnosis, treatment, and key words.

Recombinant human growth hormone is not covered by health insurance

Recombinant human growth hormone is an artificial, genetically created substance used to treat people who are short-statured. It is used as an off-label medication, but some insurance companies may deny coverage for its use.

There are many reasons why a patient’s health insurer will not cover the medication. Some denials are automatic. Others may require an appeal. The process is fairly lengthy and can be tedious. If you are denied, your doctor’s office can send an appeal. You also have the option of filing a second level appeal. This appeal can be sent to a peer-to-peer review.

Recombinant human growth hormone is a protein that can stimulate the metabolism of proteins, carbohydrates, and fats. When taken, it can help stimulate the growth of organs and tissues. It has been used to treat short stature associated with Prader-Willi syndrome, growth hormone deficiency, and chronic renal insufficiency. It is licensed for the treatment of these disorders.

However, there is still some debate about its safety. A recent study in France revealed that a 30% increase in the risk of death occurred when recombinant human growth hormone was administered. This increased risk was attributed to a combination of cardiovascular events and bone tumors. While the study is still ongoing, the FDA has indicated it is aware of its findings. They believe the benefits of recombinant growth hormone outweigh any risks.

Cost of treatment for idiopathic short stature

Idiopathic short stature (ISS) is a term used to describe children with height less than average. It is defined as a height below two standard deviations (SD) below the mean height of a given sex. In children who are extremely short, growth hormone (rhGH) injections are a common treatment. These injections are given six to seven times weekly. They are expensive, however. Each half-inch increase in height can cost $18,000 to $36,600.

Growth hormone therapy is not the only treatment for idiopathic short stature. Other treatments include somatropin, which is derived from rDNA. Treatment is controversial, as the effects of these medications are not well understood. There are also side effects, including psychiatric and behavioral problems. This means that the potential benefits of the treatment must be weighed against the considerable costs.

Growth hormone injections are costly. Patients may have to undergo several years of therapy, and there are no guarantees that the child will gain normal height. A recent study reported that these treatments do not improve the quality of life of the child. However, some children have experienced modest linear growth increases.